Louis R., Neven I., Quadvlieg V. (1997) Les cystéinyl-leucotriènes: Des médiateurs importants dans l'asthme. Rev Med Liège 52:598-602.
De lepeleire I., Reiss T.F., Rochette F. (1997) Montelukast causes prolonged, potent, leukotriene D4-receptor antagonism in the airways of patients with asthma. Clin Pharmacol Ther 61:83-92.
Reiss T.F., Hill J.B., Harman E. (1997) Increased urinary excretion of LTE4 after exercise and attenuation of exercise induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 52:1030-1035.
Leff J.A., Busse W.W., Pearlman D. (1998) Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. New Engl J Med 339:147-152.
Villaran C., O'Neill S.J., Helbling A. (1999) Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. J Allergy Clin Immunol 104:547-553.
Diamant Z., Grootendorst D., Veselic-Charvat M. (1999) The effect of montelukast (MK-0476), a cysteinyl-leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy 29:42-51.
Dempsey O., Wilson A., Sims E. (2000) Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids. Chest 117:950-953.
Gong H.J., Linn W.S., Terrell S.L. (2001) Anti-inflammatory and lung function effects of montelukast in asthmatic volunteers exposed to sulfur dioxide. Chest 119:402-408.
Reiss T.F., Altman L.C., Chervinsly P. (1996) Effects of montelukast (MK-0476), a new potent cysteinyl-leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 98:528-534.
Reiss T.F., Skorness C.A., Stricker W. (1997) Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 52:45-48.
Noonan M.J., Chervinsly P., Brandon M. (1998) Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Eur Respir J 11:1232-1239.
Knorr B., Matz J., Bernstein J. (1998) Montelukast for chronic asthma in 6-to 14-year-old children. A randomized double blind trial. JAMA 279:1181-1186.
Pizzichini E., Leff J.A., Reiss T.F. (1999) Montelukast reduces airway eosinophilic inflammation in asthma: A randomized, controlled trial. Eur Respir J 14:12-18.
Malmstrom K., Rodiguez-Gomez G., Jeremias G. (1999) Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: A randomized, controlled trial. Ann Inter Med 130:487-495.
Louis R., Lau L., Broon A. (2000) Relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 161:9-16.
Bisgaard H., Loland L., Anhoj J. (1999) NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 160:1227-1231.
Dworski R., Fitzgerald G., Sheller J. (1994) Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 149:953-959.
Löfdahl C.G., Reiss T.F., Leff J.A. (1999) Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticoids in asthmatic patients. BMJ 319:87-90.
Wechsler M., Finn D., Gunawardena D. (2000) Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 117:708-713.